- Why in news
- On 24 August 2026 the Union Health Ministry announced amendments to the Medical Devices Rules, 2017. They cover outsourced sterilization, uniform testing fees and adding the EU to the jurisdictions whose approvals can waive clinical investigation.
- What it is
- The Medical Devices Rules, 2017 regulate the manufacture, import, sale and testing of medical devices in India. They are made under the Drugs and Cosmetics Act, 1940 and are administered by the Central Drugs Standard Control Organisation (CDSCO). Devices are classified by risk and licensed accordingly.
- Rule 44 change
- Manufacturers using an outsourced sterilization facility no longer need a separate loan licence under Rule 25, if the facility holds a valid licence under the Rules.
- Ninth Schedule
- A new Ninth Schedule sets uniform fees for testing of medical devices by Medical Device Testing Laboratories.
- Rule 63 and the EU
- Rule 63 now includes the European Union among recognized stringent regulatory jurisdictions for waiver of clinical investigation for devices without predicate devices.
- Earlier recognized jurisdictions
- The provision already recognized the USA, UK, Australia, Canada and Japan.
- Parent law and regulator
- The Rules are framed under the Drugs and Cosmetics Act, 1940 and enforced by CDSCO under the Drugs Controller General of India.
- Risk classes
- Devices fall into Class A, B, C and D, with Class D the highest risk.
- Class B timeline
- Proposed cut in the manufacturing licence timeline for Class B from 140 to 115 days. Examples are BP monitors and pulse oximeters.
- Class C and D timeline
- Proposed cut from 105 to 90 days for high-risk devices such as cardiac stents and orthopaedic implants.
- Stage-wise timelines
- The draft sets defined timelines for scrutiny, audit by notified bodies, compliance verification and licence issue.
- Legal basis
- The Rules are made under the Drugs and Cosmetics Act, 1940 and administered by the CDSCO.
Don’t confuse with Medical Devices Rules, 2017 vs a separate Medical Devices Act: India has no standalone medical devices Act. The Rules operate under the Drugs and Cosmetics Act, 1940.
Don’t confuse with Loan licence vs manufacturing licence: A loan licence lets a manufacturer use another licensed firm's facilities. The amendment removes it only for outsourced sterilization.
Don’t confuse with Medical Devices Rules, 2017 vs Drugs Rules, 1945: Devices have had their own rules since 2017 (in force from January 2018). Drugs continue under the Drugs Rules, 1945.
Laws, judgments and statutory bodies: 30 Prelims questions since 2013 (what the law says, who chairs, legal basis). In Mains, 44 news-triggered questions, most in GS2, asking for provisions and challenges.
Why it matters
- Lowers compliance cost and time for manufacturers and importers.
- Uniform testing fees bring predictability and transparency, and move toward regulatory convergence.
- Faster licensing supports ease of doing business and domestic manufacturing of devices.
- Quicker approvals can improve patient access to quality-assured devices.
Problems
- Waiving clinical investigation on foreign approvals needs safeguards so patient safety and device performance suit Indian conditions.
- Testing laboratory capacity and enforcement of quality standards remain uneven.
- Shorter timelines may strain regulator and notified-body capacity and risk weaker scrutiny of high-risk devices.
Way forward
- Strengthen post-market surveillance and adverse event reporting.
- Expand notified testing laboratories and build CDSCO capacity.
- Build CDSCO and notified-body capacity and use digital tracking of applications, while keeping quality and safety audits intact.
Put in your answer
Ease of Doing Business in regulation: The amendments cut a separate licence requirement and standardize testing fees, showing regulatory simplification in health.
Risk-based classification: Four-class risk-based licensing under the 2017 Rules, with licence timelines now proposed to shrink, shows a regulatory balance between ease of business and safety.
- 2014Mains GS3 · Q11Whether antibiotic overuse causes resistance, and what monitoring and control mechanisms exist.
- 2013Mains GS3 · Q14Define fixed dose drug combinations; discuss merits and demerits.
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
No practice question for this one; the card may still help an answer. Why: Lasting regulatory topic with specific rule changes, but Prelims asks about rule amendments rarely and a Mains debate is thin. Laws are 23 of 327 Prelims questions.
Worth revising until Prelims 2028: most news questions come within two years of the event.